The table below shows TEVA PHARMACEUTICAL INDUSTRIES LTD's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$1.65B
$1.25B
$1.37B
$1.59B
$798.00M
$1.22B
Capital expenditure
-
-
-
$548.00M
$562.00M
$578.00M
Investing cash flow
$737.00M
$792.00M
$968.00M
$656.00M
$1.52B
$863.00M
Dividends paid
-
-
-
-
-
-
TEVA operating cash flow (10-K history)
TEVA PHARMACEUTICAL INDUSTRIES LTD reported operating cash flow of $1.65B for fiscal year 2025. That is up 32.2% from $1.25B in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $5.22B (FY 2016) to $1.65B. Figures come from the company's audited annual reports as filed with the SEC.
